Arch Biopartners Inc. Advances LSALT Peptide Trial for Acute Kidney Injury Prevention at Toronto General
- Arch Biopartners' LSALT peptide trial at Toronto General Hospital aims to prevent acute kidney injury in cardiac surgery patients.
- The Phase II trial will enroll 240 patients, assessing kidney injury incidence post-surgery using KDIGO criteria.
- CEO Richard Muruve emphasizes the company's commitment to innovative renal health therapies and improving patient outcomes.
Toronto General Hospital Joins Groundbreaking Clinical Trial for Acute Kidney Injury Prevention
Arch Biopartners Inc. announces a significant milestone in its clinical development efforts as Toronto General Hospital receives ethics board approval from the University Health Network (UHN) to participate in a Phase II clinical trial for the LSALT peptide. This trial aims to prevent cardiac surgery-associated acute kidney injury (CS-AKI), a condition that affects up to 30% of patients undergoing on-pump cardiac surgeries, leading to serious health complications. With this approval, Toronto General Hospital becomes the seventh site globally and the second in Canada to activate patient recruitment for this pivotal study.
The Phase II trial will enroll 240 patients in a randomized, double-blind, placebo-controlled design. Researchers will assess the incidence of acute kidney injury within seven days following on-pump cardiac surgery, using the Kidney Disease: Improving Global Outcomes (KDIGO) criteria for diagnosis. The LSALT peptide, Arch Biopartners’ lead drug candidate, seeks to reduce inflammation-induced kidney damage by targeting the dipeptidase-1 (DPEP1) pathway. Previous pre-clinical studies have indicated the peptide's potential effectiveness in preventing ischemia-reperfusion injury (IRI), which is a common complication during surgeries that can exacerbate kidney damage.
CEO Richard Muruve expresses satisfaction with the progress made in advancing the LSALT peptide trial. He highlights the importance of expanding the demographic reach of the study as recruitment efforts begin. Arch Biopartners remains committed to addressing urgent health challenges, particularly in the realm of acute kidney injury, and is simultaneously advancing other candidates like cilastatin, which focuses on preventing toxin uptake in the kidneys. This multifaceted approach underscores the company’s dedication to innovation in renal health therapies, contributing to improved surgical outcomes for patients.
In addition to the trial updates, Arch Biopartners continues to focus on the broader implications of its research on kidney health. The company's strategic direction emphasizes the critical need for therapeutic solutions that target the underlying causes of acute kidney injury, which remains a significant clinical challenge. As the Phase II trial progresses, Arch Biopartners aims to solidify its position in the biopharmaceutical landscape by delivering impactful treatments that can enhance patient care and outcomes in cardiac surgery.
As Arch Biopartners expands its clinical trial efforts, the company’s commitment to addressing urgent health needs remains clear. This trial not only amplifies the potential of the LSALT peptide but also represents a broader mission to innovate and improve the quality of care for patients facing serious health challenges related to kidney injuries.